Welcome to our dedicated page for Windtree Therapeutics news (Ticker: WINT), a resource for investors and traders seeking the latest updates and insights on Windtree Therapeutics stock.
Windtree Therapeutics, Inc. (WINT) reports developments tied to its transition from a biotechnology-focused company toward a diversified, revenue-generating operating model. Company news has covered material agreements involving cardiovascular drug candidates, licensing activity for acute pulmonary treatments, patent estate updates for istaroxime and SERCA2a activators, and clinical or regulatory disclosures related to heart failure and surfactant-based programs.
Recurring updates also include stockholder approvals, governance matters, capital actions, OTC trading status, and operating and financial results. Windtree’s disclosed product and license references include SURFAXIN®, lyophilized lucinactant, and AEROSURF®, a drug-device combination based on aerosolized KL4 surfactant delivery.
Windtree Therapeutics is advancing its study on istaroxime for early cardiogenic shock patients, highlighting the urgent need for new treatments; inpatient mortality rates reached 30% in 2020 for this condition. The company aims to complete its phase 2 study, evaluating istaroxime's effectiveness to improve blood pressure and cardiac function without severe side effects. Results are expected in Q1 2022, aiming for regulatory discussions to expedite development.
Windtree Therapeutics, Inc. (NasdaqCM: WINT) reported its Q3 2021 financial results, highlighting ongoing clinical advancements for istaroxime as a treatment for early cardiogenic shock. The company posted an operating loss of $8.1 million, a slight improvement from $8.7 million in Q3 2020. R&D expenses increased to $4.7 million, reflecting the development of istaroxime. Windtree raised $3.2 million in October 2021, bringing cash reserves to $24.5 million, expected to sustain operations for the next year. Topline data for istaroxime is anticipated in Q1 2022.
Windtree Therapeutics (NasdaqCM: WINT) announced a Notice of Allowance for a new patent by the USPTO, which will protect the istaroxime formulation until late 2039. This patent covers longer infusion durations aimed at improving treatment outcomes for acute heart failure. Following successful Phase 2 studies showing enhanced cardiac function, Windtree plans to initiate a new study in mid-2022 targeting patients with normal to low blood pressure. The ongoing development of istaroxime continues to position Windtree for future clinical advancement.
Windtree Therapeutics (NasdaqCM: WINT) will host a Key Opinion Leader (KOL) webinar on istaroxime, targeting acute heart failure, on October 19, 2021, at 8:00 am ET. Dr. John Teerlink from UCSF will present insights on current treatments and the unmet needs in acute heart failure. The event will include discussions on istaroxime's clinical development, which includes two Phase 2 trials and a Phase 2 study in early cardiogenic shock. A live Q&A will follow. Registration for the webinar is available here.
Summary not available.
Windtree Therapeutics (NasdaqCM: WINT) announced that Craig Fraser, CEO, will present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 22, 2021, at 9:55 am ET. The live webcast will be accessible via the company's Investor Events page. Windtree focuses on late-stage interventions for acute cardiovascular and pulmonary disorders, with its lead candidate, istaroxime, aimed at treating acute heart failure. They also develop AEROSURF® for respiratory distress in infants and are exploring treatments for COVID-19-related respiratory issues.
Windtree Therapeutics (WINT) reported second-quarter results for 2021, highlighting ongoing clinical trials for istaroxime and lucinactant, targeting cardiogenic shock and COVID-19 lung injury respectively. The operating loss reached $45.4 million, largely due to a $37.8 million impairment on rostafuroxin assets. R&D expenses decreased to $4.2 million, and general administrative costs were stable at $3.4 million. A net loss of $37.4 million ($1.42 per share) was recorded. The company maintains a cash position of $30 million, expected to support operations for at least the next year.
Windtree Therapeutics (NasdaqCM: WINT) has appointed Randall White, Ph.D., as Vice President of Clinical Program Management. Dr. White brings over 20 years of pharmaceutical research experience, previously serving at Daiichi Sankyo and Bristol-Myers Squibb. His expertise will support Windtree's clinical development projects. To incentivize his employment, the company granted Dr. White a stock option for 100,000 shares at the closing price on the grant date. Windtree focuses on interventions for acute cardiovascular and pulmonary disorders, with key products including istaroxime and AEROSURF®.
Windtree Therapeutics, focused on acute cardiovascular and pulmonary therapies, announced CEO Craig Fraser's upcoming presentation at the Access to Giving Virtual Investor conference from July 13-15, 2021. Windtree is scheduled to present on July 15, 2021, at 10:00 AM ET. The conference will feature over 50 companies and aims to promote investor education and advocacy, with funds raised directed to financial literacy initiatives. The presentation will be available for replay on the company’s website, and one-on-one meetings can be arranged with management.
Windtree Therapeutics (NasdaqCM: WINT) announced that CEO Craig Fraser will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 13, 2021, at 11:00 am ET. The presentation will cover the company's innovative therapies for acute cardiovascular and pulmonary disorders. Windtree is developing istaroxime for acute heart failure and AEROSURF® for respiratory distress in premature infants. A replay will be available on their investor page.